NCT06299371

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

A Prospective, Single-arm Study of Adebrelimab in Combination With Paclitaxel for Injection (Albumin Bound) and Platinum Chemotherapy as Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) Harboring Driver Gene Mutations

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Liaoning Cancer Hospital & Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, single-arm study to investigate the efficacy and safety of Adebrelimab in combination with paclitaxel for injection (albumin bound) and platinum chemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer harboring driver gene mutations

Conditions

• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Adebrelimab	Adebrelimab IV
DRUG	paclitaxel for injection (albumin bound)	paclitaxel for injection (albumin bound) IV
DRUG	Cisplatin or Carboplatin	Cisplatin or Carboplatin IV

Timeline

• Start date: 2024-04-15
• Primary completion: 2026-04-15
• Completion: 2029-04-15
• First posted: 2024-03-07
• Last updated: 2024-03-07